Revelation Biosciences granted continued listing status on Nasdaq

Revelation Biosciences (REVB) announced that the Nasdaq Hearings Panel issued a decision letter granting Revelation’s request to continue its listing on The Nasdaq Stock Market, subject to its stock trading at or above $1.00 for at least ten consecutive trading days by February 14, 2025. Additionally, the Nasdaq Hearings Panel confirmed that the company has regained compliance with the Equity Requirement of Listing Rule 5550(b)(1) for which the company was issued a notice of delisting for failure to comply with Equity Requirement of Listing Rule 5550(b)(1) on August 14, 2024.